Patent US4148920A successfully refreshed from Google Patents.
US4148920A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic L- and DL- phenylglycines to treat diseases or disorders of reduced blood flow or oxygen availability
Assignee: Pfizer Inc
•
Filing: 1977-09-19
•
Granted: 1979-04-10
•
Expires: 1997-09-19
Abstract
Abstract L- and DL- Phenylglycines of the formula <IMAGE> (I) and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R1 is NH2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.
Inventors
- 👤 Ian T. Barnish
- 👤 Peter E. Cross
- 👤 John C. Danilewicz
- 👤 Malcolm Morville
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 14:27
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/165; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/22; A61P; A61P3/00; A61P3/04; A61P3/08; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
68 words
A method of treating a mammalian subject suffering from a disease or condition attributable to reduced blood flow or oxygen availability, which comprises orally or parenterally administering to said subject a blood flow or oxygen availability increasing amount of the L- or DL- form of a compound of the formula: ##STR3## or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl and R 1 is OH.
Claim 2
Independent Claim
68 words
A method of treating a mammalian subject suffering from a disease or condition attributable to reduced blood flow or oxygen availability, which comprises orally or parenterally administering to said subject a blood flow or oxygen availability increasing amount of the L- or DL- form of a compound of the formula: ##STR3## or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl and R 1 is OH.
Claim 3
Dependent Claim
11 words
A method according to claim 1 wherein said compound is DL-2-(4-hydroxyphenyl)glycine.
Claim 4
Dependent Claim
11 words
A method according to claim 1 wherein said compound is L(+)-2-(4-hydroxyphenyl)glycine.
Claim 5
Dependent Claim
11 words
A method according to claim 1 wherein said compound is L(+)-2-(4-methoxyphenyl)glycine.
Claim 6
Dependent Claim
34 words
A method according to claim 1 wherein said subject is a human and from about 0.5 to 10 mg/kg of the L- form of said compound is administered up to five times a day.
Claim 7
Dependent Claim
30 words
A method according to claim 5 wherein said compound is administered orally in the form of tablets or capsules each containing from about 25 to 700 mg. of said compound.
Claim 8
Dependent Claim
32 words
A method according to claim 5 wherein said compound is administered parenterally in the form of a solution containing from about 5 to 35 mg. of said compound per ml. of solution.
References Cited (Backward Citations)
US3976680A
Cited
US4016205A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-09 | 1982-10-09 | 1983-04-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-09 | 1986-10-09 | 1987-04-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-09 | 1990-10-09 | 1991-04-10 | $7700.00 | Window Closed / Lapsed |